Pharnext to Present at 7th Annual CEC Capital Summit
Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA) , a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the 7th Annual CEC Capital Summit.
The presentation will take place as follows:
- Date: Wednesday, September 20th , 2017
- Time: 2:50 pm PDT (11:50 pm CEST)
- Venue: Montage Beverly Hills in Beverly Hills, California
If you are interested in meeting the Pharnext management team during this event, please send an email to Matthew Shinseki at firstname.lastname@example.org .
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Growth Stock Exchange in
Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com
Xavier Paoli, +33 (0)1 41 09 22 30
Chief Commercial Officer
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
Media Relations (Europe)
+33 (0)1 44 54 36 64
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212-362-1200
Media Relations (U.S.)
Financial Communication (France)
Emmanuel Huynh, +33 (0)1 44 71 20 40
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
PA-PMI22.1.2018 18:00 | pressemeddelelse
PMI’s Salary Survey Reveals that Project Management Practitioners with the PMP Certification Earn 23% More
ABB22.1.2018 16:43 | pressemeddelelse
ABB and City of Davos Pave the Way to Sustainable Mobility Through E-Vehicle Innovation
FERRING-PHARMACEUTICALS22.1.2018 15:02 | pressemeddelelse
Ferring enters into worldwide OmniAb® platform license agreement with Ligand
NY-CALVIN-KLEIN22.1.2018 15:02 | pressemeddelelse
Calvin Klein, Inc. Announces the Spring/Summer 2018 Calvin Klein Underwear and Calvin Klein Jeans Global Advertising Campaign
VA-HILTON22.1.2018 14:02 | pressemeddelelse
Hilton Led Hospitality Industry in Customer Innovations and Recorded Best Ever Growth in 2017
MA-TAKEDA-PHARMACEUTICAL22.1.2018 14:02 | pressemeddelelse
European Commission Approves ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy– Providing an Innovative Treatment Option to Patients
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum